Bifidobacterium breve Bif195 ameliorates aspirin-induced gastric mucosal damage: A randomised, double blind, placebo-controlled crossover trial.
Nina LønSara EngelAnders DamholtBrynjulf MortensenAnne B HaaberAnja WellejusFilip K Krag KnopPublished in: Alimentary pharmacology & therapeutics (2023)
Bif195 reduces aspirin-induced gastric mucosal damage and may serve as a safe supplement during multiple-dosing aspirin treatment.
Keyphrases
- placebo controlled
- double blind
- phase iii
- clinical trial
- low dose
- study protocol
- phase ii
- diabetic rats
- high glucose
- cardiovascular events
- antiplatelet therapy
- open label
- oxidative stress
- phase ii study
- randomized controlled trial
- ulcerative colitis
- acute coronary syndrome
- drug induced
- mouse model
- percutaneous coronary intervention
- combination therapy
- smoking cessation
- locally advanced